cagrisema semaglutide cagrilintide phase 3 results 2024 2025 obesity Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study A stronger Ozempic is coming.
A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




